The Placenta as a Window to Cardiovascular Health: What Your Delivery Room Never Explained

The placenta functions as a nine-month cardiovascular stress test that produces detailed vascular pathology findings for every pregnant woman. When spiral artery remodeling fails, when infarcts accumulate, when fibrin deposits encase the villi, the placenta is documenting maternal vascular dysfunction with precision no other organ can match. Women with decidual arteriopathy face a 3.2-fold increased risk of hypertension within a decade, according to research published in Hypertension (Catov 2019). Yet after delivery, this organ and its diagnostic wealth are discarded in a biohazard bag.

The Organ That Tests Your Arteries

The placenta is the most underutilized diagnostic tool in women’s cardiovascular medicine. It grows for nine months, does extraordinary vascular biology, fails when the mother’s vasculature fails, and is then thrown away.

I have watched this happen hundreds of times. A woman delivers after a pregnancy complicated by preeclampsia at 34 weeks. Her blood pressure normalizes. She is discharged with instructions to follow up with her obstetrician. The placenta, which could have told us whether she had decidual arteriopathy, whether her spiral arteries remodeled, whether chronic ischemia left its signature in infarcts and fibrin, goes into the pathology waste stream without a second glance.

Eighteen years later, she presents to my cardiology clinic with a first myocardial infarction.

This is not bad luck. This is a systems failure with a body count.

The placenta is the only organ in medicine that we grow specifically to test vascular function, that reliably reflects maternal endothelial health, and that we routinely discard without examination. No other diagnostic opportunity in cardiovascular medicine is so consistently wasted.

To understand why the placenta matters, you must understand what it demands from the maternal circulation. Successful placentation requires extravillous trophoblast cells to invade the uterine wall and completely remodel the maternal spiral arteries. These arteries begin as 200-300 micrometer high-resistance vessels. By 20 weeks gestation, they must become 2-3 millimeter low-resistance conduits. 5 / Solid

This is not a subtle change. It is a complete architectural transformation. The muscular walls of the spiral arteries are destroyed and replaced with fibrinoid material. The arteries lose their ability to constrict. Blood flow to the placenta increases from nearly nothing to 600-800 milliliters per minute by term.

When this remodeling fails, everything downstream fails with it.

The Biology of Maternal Vascular Malperfusion

The core lesion in placental dysfunction has a name: maternal vascular malperfusion. This term describes the constellation of findings that result when spiral artery remodeling is incomplete or absent.

In normotensive pregnancies, greater than 90% of spiral arteries undergo adequate remodeling. In preeclamptic pregnancies, that number drops to 30-50% Brosens 2017. The unremodeled arteries remain high-resistance vessels. They deliver blood to the intervillous space in pulsatile jets rather than steady flow. The placenta experiences chronic hypoxia and oxidative stress. 5 / Solid

The placenta responds to this ischemia with a characteristic antiangiogenic program. Soluble fms-like tyrosine kinase 1, or sFlt-1, is released in excess. This protein binds and neutralizes vascular endothelial growth factor and placental growth factor. The resulting imbalance, elevated sFlt-1 with suppressed VEGF and PlGF, produces systemic endothelial dysfunction in the mother. Her blood vessels lose their ability to dilate appropriately. Her blood pressure rises. Her kidneys spill protein. Her liver enzymes climb.

This is preeclampsia. And it is not a pregnancy disease. It is a vascular disease that pregnancy unmasks.

The sFlt-1/PlGF imbalance is measurable in maternal blood weeks before clinical symptoms appear. A ratio above 38 predicts preeclampsia with sensitivity exceeding 80% Goonewardene 2020. But even after the pregnancy ends and the sFlt-1 source is removed, the maternal endothelium does not fully recover. Endothelial dysfunction persists. Flow-mediated dilation remains impaired years after delivery. The pregnancy is over. The vascular injury is permanent. 4 / Promising

Women don’t die from what they have. Women die from what they hold.

The placenta holds the evidence of vascular vulnerability. It holds the documentation of remodeling failure. It holds the proof that this woman’s endothelium was already compromised before pregnancy revealed it. And we throw it away.

What the Pathologist Sees

When a placenta is examined by a pathologist trained in perinatal pathology, the findings fall into recognizable patterns. Each pattern tells a different story about maternal vascular health.

Decidual arteriopathy is the most direct marker of systemic vascular disease. This term encompasses several findings: acute atherosis, which looks strikingly similar to early atherosclerotic lesions with fibrinoid necrosis and foam cell infiltration; mural hypertrophy of the decidual vessels; and persistence of intact muscular walls in vessels that should have been remodeled.

The Catov study followed women for a decade after delivery and found that decidual arteriopathy predicted hypertension independent of whether the pregnancy met criteria for preeclampsia Catov 2019. The hazard ratio was 3.2 with a 95% confidence interval of 1.8 to 5.7. The placenta identified women at risk even when their clinical course was unremarkable.

Placental infarcts tell a story of cumulative ischemia. Small infarcts, less than 1 centimeter, are common and usually insignificant. Large infarcts, greater than 3 centimeters, are rare in uncomplicated pregnancies, appearing in fewer than 2% of term deliveries. In severe preeclampsia and intrauterine growth restriction, 40-60% of placentas contain multiple large infarcts Burton & Jauniaux 2020. 5 / Solid

Massive perivillous fibrin deposition occurs when more than 50% of villi become encased in fibrin. This finding indicates severe, prolonged uteroplacental insufficiency. It is associated with recurrent pregnancy loss, growth restriction, and fetal demise. The same thrombotic and inflammatory mechanisms that produce MPFD in the placenta produce thrombotic and inflammatory disease in the maternal coronary arteries.

The SCOPE study, a prospective cohort of first pregnancies, found maternal vascular malperfusion in 58% of placentas from early-onset preeclampsia Siddiqui 2021. The placenta was telling us something. We were not listening.

The Cardiovascular Implications Framework

I propose a framework for understanding placental findings: The Placental Vascular Report Card. Just as a stress test reports on myocardial perfusion, the placenta reports on maternal vascular function. The report has three grades.

Grade A indicates normal spiral artery remodeling, no significant infarcts, no decidual arteriopathy. The maternal vascular system passed the stress test of pregnancy.

Grade B indicates partial remodeling failure, scattered small infarcts, or borderline findings. The maternal vascular system showed strain. Cardiovascular surveillance should be enhanced.

Grade C indicates decidual arteriopathy, multiple large infarcts, massive perivillous fibrin deposition, or severe malperfusion. The maternal vascular system failed the stress test. Cardiovascular intervention should begin immediately.

This framework does not yet appear in guidelines. It should.

The evidence base supporting enhanced surveillance is substantial. A meta-analysis of adverse pregnancy outcomes found that preeclampsia confers a 4.8-fold higher risk of later hypertension Hauspurg 2023. Preterm birth doubles cardiovascular disease risk. Intrauterine growth restriction increases coronary heart disease risk by 60%. These associations persist when adjusted for traditional cardiovascular risk factors. 5 / Solid

The American Heart Association now recognizes adverse pregnancy outcomes as cardiovascular risk enhancers. The 2023 ACC/AHA guidelines on chronic coronary disease include pregnancy history in risk assessment. But guidelines that mention pregnancy complications without examining the placenta are guidelines that accept secondhand evidence when primary evidence exists.

Why Hospitals Discard Diagnostic Gold

The reasons placentas are not routinely examined are administrative, not scientific.

Pathological examination costs $200-400 per specimen. Pathologist time is finite. Current guidelines from the College of American Pathologists recommend examination only for specific indications: preterm birth, growth restriction, preeclampsia, stillbirth, neonatal seizures, certain infections. This means that many placentas from complicated pregnancies are examined, but many are not.

The larger problem is communication. Even when placentas are examined, the findings rarely reach the woman’s primary care physician or future cardiologist. The pathology report sits in the obstetric record. The obstetrician may discuss findings at the postpartum visit. The woman may hear words like “some calcification” or “normal aging changes” that minimize the significance. By the time she establishes care with an internist or cardiologist, years have passed. No one asks about her placental pathology. She could not answer if they did.

This is a communication failure with cardiovascular consequences.

The fix is not complicated. Every woman who delivers should receive a summary of her pregnancy cardiovascular profile: blood pressure trajectory, preterm vs. term delivery, fetal growth percentile, placental pathology findings if examined. This summary should be a permanent part of her medical record. It should be automatically flagged in any electronic health record when she presents to a primary care physician, cardiologist, or emergency department.

The technology exists. The will does not.

Gestational Hypertension Versus Preeclampsia: Why the Specific Diagnosis Determines Your Long-Term Risk

Women are frequently discharged from obstetric care with a note that they had “high blood pressure in pregnancy” without understanding the clinical and long-term risk distinctions between gestational hypertension, preeclampsia, superimposed preeclampsia, and HELLP syndrome. These are not interchangeable descriptions of the same event. Each carries a different magnitude of cardiovascular risk over the subsequent decades, and the specific diagnosis matters for how aggressively surveillance should be pursued in the years and decades after delivery.

Gestational hypertension is defined as a blood pressure at or above 140/90 mmHg that develops after 20 weeks of gestation in a previously normotensive woman, without proteinuria or maternal organ dysfunction. It is the mildest hypertensive disorder of pregnancy but is not without long-term significance. Women with gestational hypertension have approximately a 3-fold higher risk of developing chronic hypertension compared with women whose blood pressure remained normal throughout pregnancy, based on meta-analytic data across multiple prospective cohort studies.

Preeclampsia is defined as gestational hypertension with the addition of either proteinuria or evidence of maternal organ dysfunction, including thrombocytopenia, renal impairment, hepatic enzyme elevation, pulmonary edema, or new-onset headache unresponsive to analgesia. Preeclampsia carries substantially higher long-term cardiovascular risk. The Hauspurg meta-analysis, published in Circulation in 2023, quantified the risk: preeclampsia confers a 4.8-fold increased risk of hypertension over 10 years and approximately a 2.3-fold increased risk of ischemic heart disease over 15 to 20 years. Early-onset preeclampsia, defined as delivery before 34 weeks, carries the highest long-term risk within the preeclampsia spectrum; women who deliver very early represent the cases where placental vascular dysfunction is most severe and systemic endothelial compromise is most extensive.

Superimposed preeclampsia develops in a woman who already had chronic hypertension before or early in pregnancy. The baseline vascular dysfunction underlying the pre-existing hypertension is compounded by the additional preeclamptic physiology. Women with superimposed preeclampsia have the most severe maternal organ involvement and the highest long-term cardiovascular risk among the hypertensive pregnancy disorders.

HELLP syndrome, characterized by hemolysis, elevated liver enzymes, and low platelet count, represents the most severe end of the preeclampsia spectrum. The degree of organ system involvement in HELLP reflects profound vascular and endothelial pathology. Women who experience HELLP face not only the long-term cardiovascular sequelae of preeclampsia but also ongoing hepatic monitoring needs and cardiovascular surveillance at a level consistent with the underlying disease severity.

For women reviewing their pregnancy history, the clinical question to answer is not “did I have high blood pressure” but “what specific diagnosis appears in my discharge summary, and how early did it occur?” The distinction between gestational hypertension and early-onset preeclampsia, between preeclampsia and HELLP, represents a meaningful difference in the magnitude of cardiovascular risk and the urgency with which surveillance should be established. A woman who cannot answer this question from memory should request her obstetric records before her next cardiovascular appointment.

What You Should Do Now

If you are currently pregnant or planning pregnancy, understand that your pregnancy will produce cardiovascular data. Request that your placenta be examined if you develop preeclampsia, deliver preterm, have a growth-restricted baby, or experience placental abruption. Ask for a copy of the pathology report. Keep it with your medical records.

If you have already delivered and experienced pregnancy complications, the pregnancy itself is diagnostic even without placental pathology. Preeclampsia alone confers enough risk to warrant enhanced cardiovascular surveillance. You do not need the pathology report to justify attention to your vascular health. But you should know that the information existed and was discarded.

At your next primary care or cardiology visit, bring your pregnancy history. Not a vague summary. Specific details: gestational age at delivery, birth weight percentile, blood pressure readings, any diagnoses of preeclampsia or gestational hypertension. If you have placental pathology, bring the report.

Then request these four tests by name: ApoB, Lp(a), fasting insulin, and hs-CRP. These are not part of standard screening. They should be. They capture cardiovascular risk that conventional lipid panels miss. For a woman with adverse pregnancy outcomes, these tests may reveal treatable risk factors years before symptoms develop.

The placenta spent nine months documenting your vascular biology. The least we can do is read the report.

Frequently Asked Questions

Should I request my placenta be examined after delivery?

If your pregnancy was complicated by preeclampsia, preterm birth before 37 weeks, fetal growth restriction below the 10th percentile, placental abruption, or unexplained stillbirth, you should request formal pathological examination. Ask your obstetrician to order it before delivery if possible. The findings should be documented in your medical record and communicated to whoever will manage your long-term health. You have the right to request a copy of the pathology report. Keep it with your important medical documents. If your pregnancy was uncomplicated, routine examination is not standard practice, but you can still request it if you want the information. The cost may or may not be covered by insurance.

What placental findings predict future heart disease?

Four findings carry the strongest cardiovascular signal. Decidual arteriopathy, which includes acute atherosis and mural hypertrophy of the decidual vessels, predicts hypertension with a 3.2-fold increased risk over 10 years. Failed spiral artery remodeling, documented as persistent muscular walls in arteries that should have been transformed, indicates the fundamental lesion underlying preeclampsia and reflects systemic endothelial dysfunction. Placental infarcts greater than 3 centimeters, especially multiple infarcts, indicate chronic uteroplacental ischemia and correlate with future coronary disease. Massive perivillous fibrin deposition, where more than 50% of villi are encased in fibrin, reflects severe thrombotic and inflammatory pathology that extends beyond pregnancy.

How long after pregnancy does cardiovascular risk from placental dysfunction persist?

The risk is permanent because the placenta did not create the vascular vulnerability. It revealed vulnerability that was already present. Studies following women 20-30 years after preeclamptic pregnancies show persistently elevated rates of hypertension, coronary artery disease, stroke, and heart failure. A woman who had preeclampsia at age 28 has elevated risk at age 48, at age 58, and at age 68. The risk does not fade with time. It compounds with aging and the accumulation of additional risk factors. This is why pregnancy complications should be considered lifetime cardiovascular risk markers, not resolved historical events.

My pregnancy was complicated but my placenta was not examined. What should I do now?

The pregnancy complication itself provides diagnostic information even without placental pathology. Preeclampsia, preterm birth, and fetal growth restriction are all independent predictors of cardiovascular disease in large prospective studies. You already have evidence of vascular vulnerability. Act on it now. Schedule cardiovascular risk assessment with your primary care physician or a cardiologist. Request ApoB, Lp(a), fasting insulin, and hs-CRP in addition to standard lipid testing. Discuss your pregnancy history explicitly. Many physicians do not ask about obstetric history when assessing cardiovascular risk. You must volunteer the information. Consider it equivalent in importance to family history of heart disease.

Why do hospitals discard placentas without examination?

The answer is economics and workflow, not medical judgment about diagnostic value. Pathological examination costs $200-400 per specimen and requires pathologist time, which is constrained in most health systems. Current professional society guidelines recommend examination only for specific clinical indications, not routine screening. This conservative approach reflects cost-benefit analysis that weighs immediate examination costs against uncertain future benefits. But this calculus ignores the downstream cardiovascular costs that accrue when vascular risk goes unrecognized for decades. It is a systems failure. The information has value. The system is not structured to capture that value. Advocacy for policy change at institutional and professional society levels is needed to change this practice.